Cerus (CERS) Competitors $2.43 +0.09 (+3.85%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$2.40 -0.03 (-1.23%) As of 07:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CERS vs. NEOG, STAA, QDEL, OSUR, and UTMDShould you buy Cerus stock or one of its competitors? MarketBeat compares Cerus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cerus include Neogen (NEOG), STAAR Surgical (STAA), QuidelOrtho (QDEL), OraSure Technologies (OSUR), and Utah Medical Products (UTMD). These companies are all part of the "health care supplies" industry. CERS vs. NEOGCERS vs. STAACERS vs. QDELCERS vs. OSURCERS vs. UTMDHow does Cerus compare to Neogen?Cerus (NASDAQ:CERS) and Neogen (NASDAQ:NEOG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk. Does the media favor CERS or NEOG? In the previous week, Neogen had 2 more articles in the media than Cerus. MarketBeat recorded 3 mentions for Neogen and 1 mentions for Cerus. Cerus' average media sentiment score of 1.32 beat Neogen's score of 1.20 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neogen 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CERS or NEOG more profitable? Cerus has a net margin of -4.41% compared to Neogen's net margin of -69.93%. Neogen's return on equity of 2.35% beat Cerus' return on equity.Company Net Margins Return on Equity Return on Assets Cerus-4.41% -15.18% -4.38% Neogen -69.93%2.35%1.46% Which has more volatility & risk, CERS or NEOG? Cerus has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market. Comparatively, Neogen has a beta of 1.84, suggesting that its stock price is 84% more volatile than the broader market. Do insiders and institutionals hold more shares of CERS or NEOG? 78.4% of Cerus shares are held by institutional investors. Comparatively, 96.7% of Neogen shares are held by institutional investors. 3.4% of Cerus shares are held by insiders. Comparatively, 0.6% of Neogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better valuation and earnings, CERS or NEOG? Cerus has higher earnings, but lower revenue than Neogen. Cerus is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCerus$206.13M2.36-$15.63M-$0.05N/ANeogen$894.66M2.08-$1.09B-$2.80N/A Do analysts recommend CERS or NEOG? Cerus currently has a consensus price target of $4.00, suggesting a potential upside of 64.61%. Neogen has a consensus price target of $10.67, suggesting a potential upside of 24.61%. Given Cerus' stronger consensus rating and higher probable upside, equities analysts plainly believe Cerus is more favorable than Neogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cerus 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Neogen 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 SummaryCerus beats Neogen on 8 of the 15 factors compared between the two stocks.How does Cerus compare to STAAR Surgical?STAAR Surgical (NASDAQ:STAA) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation. Do insiders and institutionals believe in STAA or CERS? 96.7% of STAAR Surgical shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 39.9% of STAAR Surgical shares are held by company insiders. Comparatively, 3.4% of Cerus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, STAA or CERS? Cerus has lower revenue, but higher earnings than STAAR Surgical. STAAR Surgical is trading at a lower price-to-earnings ratio than Cerus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSTAAR Surgical$239.44M6.72-$80.45M-$0.43N/ACerus$206.13M2.36-$15.63M-$0.05N/A Do analysts recommend STAA or CERS? STAAR Surgical currently has a consensus price target of $27.81, indicating a potential downside of 13.92%. Cerus has a consensus price target of $4.00, indicating a potential upside of 64.61%. Given Cerus' stronger consensus rating and higher probable upside, analysts clearly believe Cerus is more favorable than STAAR Surgical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score STAAR Surgical 2 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.09Cerus 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Does the media favor STAA or CERS? In the previous week, STAAR Surgical had 29 more articles in the media than Cerus. MarketBeat recorded 30 mentions for STAAR Surgical and 1 mentions for Cerus. Cerus' average media sentiment score of 1.32 beat STAAR Surgical's score of 0.57 indicating that Cerus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STAAR Surgical 7 Very Positive mention(s) 8 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive Cerus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is STAA or CERS more profitable? Cerus has a net margin of -4.41% compared to STAAR Surgical's net margin of -7.24%. STAAR Surgical's return on equity of 3.31% beat Cerus' return on equity.Company Net Margins Return on Equity Return on Assets STAAR Surgical-7.24% 3.31% 2.55% Cerus -4.41%-15.18%-4.38% Which has more risk & volatility, STAA or CERS? STAAR Surgical has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Cerus has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market. SummarySTAAR Surgical and Cerus tied by winning 8 of the 16 factors compared between the two stocks.How does Cerus compare to QuidelOrtho?QuidelOrtho (NASDAQ:QDEL) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment. Do analysts prefer QDEL or CERS? QuidelOrtho currently has a consensus target price of $14.88, suggesting a potential upside of 37.22%. Cerus has a consensus target price of $4.00, suggesting a potential upside of 64.61%. Given Cerus' stronger consensus rating and higher possible upside, analysts plainly believe Cerus is more favorable than QuidelOrtho.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score QuidelOrtho 3 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Cerus 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has more risk & volatility, QDEL or CERS? QuidelOrtho has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Cerus has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market. Does the media refer more to QDEL or CERS? In the previous week, QuidelOrtho had 4 more articles in the media than Cerus. MarketBeat recorded 5 mentions for QuidelOrtho and 1 mentions for Cerus. Cerus' average media sentiment score of 1.32 beat QuidelOrtho's score of 0.57 indicating that Cerus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QuidelOrtho 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cerus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of QDEL or CERS? 99.0% of QuidelOrtho shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 0.8% of QuidelOrtho shares are owned by insiders. Comparatively, 3.4% of Cerus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable valuation & earnings, QDEL or CERS? Cerus has lower revenue, but higher earnings than QuidelOrtho. Cerus is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuidelOrtho$2.66B0.28-$1.13B-$17.82N/ACerus$206.13M2.36-$15.63M-$0.05N/A Is QDEL or CERS more profitable? Cerus has a net margin of -4.41% compared to QuidelOrtho's net margin of -45.57%. QuidelOrtho's return on equity of 4.25% beat Cerus' return on equity.Company Net Margins Return on Equity Return on Assets QuidelOrtho-45.57% 4.25% 1.56% Cerus -4.41%-15.18%-4.38% SummaryCerus beats QuidelOrtho on 10 of the 16 factors compared between the two stocks.How does Cerus compare to OraSure Technologies?OraSure Technologies (NASDAQ:OSUR) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment. Does the media favor OSUR or CERS? In the previous week, OraSure Technologies had 6 more articles in the media than Cerus. MarketBeat recorded 7 mentions for OraSure Technologies and 1 mentions for Cerus. Cerus' average media sentiment score of 1.32 beat OraSure Technologies' score of 1.12 indicating that Cerus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OraSure Technologies 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cerus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in OSUR or CERS? 93.5% of OraSure Technologies shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 3.9% of OraSure Technologies shares are owned by company insiders. Comparatively, 3.4% of Cerus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer OSUR or CERS? OraSure Technologies currently has a consensus price target of $3.00, indicating a potential downside of 0.33%. Cerus has a consensus price target of $4.00, indicating a potential upside of 64.61%. Given Cerus' stronger consensus rating and higher possible upside, analysts clearly believe Cerus is more favorable than OraSure Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OraSure Technologies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Cerus 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Is OSUR or CERS more profitable? Cerus has a net margin of -4.41% compared to OraSure Technologies' net margin of -66.42%. Cerus' return on equity of -15.18% beat OraSure Technologies' return on equity.Company Net Margins Return on Equity Return on Assets OraSure Technologies-66.42% -18.57% -15.71% Cerus -4.41%-15.18%-4.38% Which has more risk and volatility, OSUR or CERS? OraSure Technologies has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Cerus has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market. Which has higher valuation and earnings, OSUR or CERS? Cerus has higher revenue and earnings than OraSure Technologies. Cerus is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOraSure Technologies$115.02M1.80-$68.73M-$1.04N/ACerus$206.13M2.36-$15.63M-$0.05N/A SummaryCerus beats OraSure Technologies on 12 of the 16 factors compared between the two stocks.How does Cerus compare to Utah Medical Products?Utah Medical Products (NASDAQ:UTMD) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability. Do analysts recommend UTMD or CERS? Cerus has a consensus price target of $4.00, indicating a potential upside of 64.61%. Given Cerus' stronger consensus rating and higher probable upside, analysts plainly believe Cerus is more favorable than Utah Medical Products.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Cerus 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Does the media favor UTMD or CERS? In the previous week, Utah Medical Products had 2 more articles in the media than Cerus. MarketBeat recorded 3 mentions for Utah Medical Products and 1 mentions for Cerus. Cerus' average media sentiment score of 1.32 beat Utah Medical Products' score of 0.32 indicating that Cerus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Utah Medical Products 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cerus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in UTMD or CERS? 69.6% of Utah Medical Products shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 8.0% of Utah Medical Products shares are held by insiders. Comparatively, 3.4% of Cerus shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable earnings & valuation, UTMD or CERS? Utah Medical Products has higher earnings, but lower revenue than Cerus. Cerus is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUtah Medical Products$38.52M5.28$11.29M$3.3818.93Cerus$206.13M2.36-$15.63M-$0.05N/A Which has more volatility & risk, UTMD or CERS? Utah Medical Products has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market. Comparatively, Cerus has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Is UTMD or CERS more profitable? Utah Medical Products has a net margin of 28.90% compared to Cerus' net margin of -4.41%. Utah Medical Products' return on equity of 9.13% beat Cerus' return on equity.Company Net Margins Return on Equity Return on Assets Utah Medical Products28.90% 9.13% 8.86% Cerus -4.41%-15.18%-4.38% SummaryUtah Medical Products beats Cerus on 9 of the 16 factors compared between the two stocks. Get Cerus News Delivered to You Automatically Sign up to receive the latest news and ratings for CERS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERS vs. The Competition ExportMetricCerusMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$468.86M$8.09B$6.25B$12.29BDividend YieldN/A2.53%2.80%5.32%P/E Ratio-48.6016.0020.6425.23Price / Sales2.366.07554.8579.36Price / CashN/A16.7427.4837.30Price / Book7.153.589.666.63Net Income-$15.63M$224.05M$3.56B$335.59M7 Day Performance-4.71%-2.35%-1.65%-1.20%1 Month Performance16.83%-3.00%-2.60%-1.16%1 Year Performance84.09%0.66%30.07%28.10% Cerus Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CERSCerus2.5125 of 5 stars$2.43+3.8%$4.00+64.6%+82.7%$468.86M$206.13MN/A290Positive NewsNEOGNeogen2.0059 of 5 stars$8.50-1.8%$10.67+25.5%+29.5%$1.85B$894.66MN/A2,110Positive NewsSTAASTAAR Surgical2.2438 of 5 stars$27.62-0.8%$19.93-27.8%+68.1%$1.38B$239.44MN/A1,211Earnings ReportAnalyst UpgradeQDELQuidelOrtho3.359 of 5 stars$10.57+6.1%$14.88+40.8%-67.6%$719.88M$2.73BN/A6,500OSUROraSure Technologies2.3176 of 5 stars$3.04+0.5%$3.00-1.2%+23.9%$218.43M$115.02MN/A840 Related Companies and Tools Related Companies NEOG Competitors STAA Competitors QDEL Competitors OSUR Competitors UTMD Competitors ANIK Competitors WST Competitors ALGN Competitors COO Competitors MMSI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CERS) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerus Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
